← boardnext 2027-05
TELO
Telomir Pharmaceuticals, Inc.distress 8/10 · high distress / dilution risk$1.13+7%today-51% from 52w high
Lead: Wilson's disease
Revenue
pre-revenue
Liquidity
$1M
Runway
0.2 yrs
Shares 1y
+113%
Price & events
-15.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+6.6%
1D
-5.0%
1W
-9.6%
1M
-18.1%
3M
-15.7%
6M
-45.1%
1Y
-72.0%
2Y
—
5Y
-77.4%
All
Overview
- Market Cap
- $77.72M
- Volume
- 9.37K
- 52 Week Range
- $0.92 – $2.29
- Total Shares
- 68.77M
- Float Shares
- 47.51M
- Short %
- 1.73%
- % Held by Insiders
- 35.10%
- % Held by Institutions
- 3.26%
- RVOL
- 0.07x
- Beta
- -0.24
Pipeline stages · 1 programs
Zn-Telomir
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-05 Estimated 50% readout ~2027-06-15 | Phase 1/2 | Zn-Telomir | Triple-Negative Breast Cancer (TNBC), Advanced Triple-Negative Breast Cancer, Metastatic Triple-negative Breast Cancer | — | not yet recruiting |
Catalyst news & presentations · 5
- 2026Guided 40%conferencedata presentationsecondaryTelomir-1 · Abstract submissions and presentations at oncology-focused scientific conferences.SEC 8-K
- first half of 2026trial initiationsecondaryPhase 1/2Telomir-Zn · Initiate first-in-human Phase 1/2 trial in advanced or metastatic triple-negative breast cancer.SEC 8-K
- 2026-06-15fda agreementTelomir-Zn · FDA cleared IND for Phase 1/2 trial in triple-negative breast cancerSEC 8-K
- first quarter of 2026regulatory submissionFiled (NDA/BLA)Telomir-1 · Submit IND application to FDA.SEC 8-K
- by year-endregulatory submissionFiled (NDA/BLA)Telomir-1 · IND submission for Telomir-1SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Wilson's disease
- none identified
Recent news
- 2026-06-18Telomir Pharmaceuticals Inc (TELO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
- 2026-06-15Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model - ACCESS Newswire
- 2026-06-15Telomir (NASDAQ: TELO) adds Telomir-Zn diabetes data to support FDA-cleared TNBC trial - Stock Titan
- 2026-06-10Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Despite Positive Stock Reaction - Revenue Report - dars.gov.et
- 2026-05-26Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider Than Expected Loss Highlights Pre-Revenue Challenges - Quarterly Earnings - dars.gov.et
- 2026-05-20Study links Telomir-Zn to better survival in toxic copper buildup disorder - Stock Titan
- 2026-04-30Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer - ACCESS Newswire
- 2026-04-24Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) - ACCESS Newswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.